Lenvima (lenvatinib) — Medica

Renal cell carcinoma

Initial criteria

age ≥ 18 years
Patient has advanced disease
Patient meets ONE of the following (i or ii):
i. Lenvima is used in combination with Keytruda (pembrolizumab intravenous infusion); OR
ii. Lenvima is used in combination with everolimus tablets/Afinitor Disperz (everolimus tablets for oral suspension) AND patient meets one of the following (a or b): a) patient has clear cell histology and has tried one antiangiogenic therapy (e.g., axitinib, pazopanib, sunitinib, cabozantinib); OR b) patient has non-clear cell histology

1 year